Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.51 |
| ▸ | CNR1 | P21554 | 7/20 | 0.51 |
| ▸ | UGCG | Q16739 | 4/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1337790 | 1.00 | CNR2 (0.51) | CNR2CNR1UGCGGRIA2 | |
| SCHEMBL1337501 | 0.89 | UGCG (0.43) | CNR2CNR1UGCGGRIA2 | |
| SCHEMBL1337506 | 0.89 | UGCG (0.43) | CNR2CNR1UGCGGRIA2 | |
| SCHEMBL12127916 | 0.84 | UGCG (0.45) | CNR2CNR1UGCGGRIA2 | |
| SCHEMBL12129634 | 0.84 | UGCG (0.40) | CNR2CNR1UGCG | |
| SCHEMBL12127917 | 0.83 | UGCG (0.42) | CNR2CNR1UGCGGRIA2 | |
| SCHEMBL1337801 | 0.82 | CNR2 (0.49) | CNR2CNR1UGCGGRIA2 | |
| SCHEMBL1337805 | 0.82 | CNR2 (0.49) | CNR2CNR1UGCGGRIA2 | |
| SCHEMBL13261143 | 0.82 | UGCG (0.39) | CNR2CNR1UGCGGRIA2 | |
| SCHEMBL12127923 | 0.82 | UGCG (0.46) | CNR2CNR1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653127-B2 | Bicyclic pyrazolo-heterocycles | CARA THERAPEUTICS, INC. (US) | 2014-02-18 | — | — | US | claimed |
| EP-2391627-B1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | claimed |
| US-8653127-B2 | Bicyclic pyrazolo-heterocycles | CARA THERAPEUTICS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2391627-B1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-2391627-A2 | BICYCLIC PYRAZOLO-HETEROCYCLES | Cara Therapeutics, Inc. (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20110275609-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2010088050-A2 | BICYCLIC PYRAZOLO-HETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275609-A1 | BICYCLIC PYRAZOLO-HETEROCYCLES | CNR1, CNR2, HRH4 | CNR2 2/4885CNR1 1/4885UGCG 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.